Apollo Endosurgery Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 1.95% of US listed stocks.
APEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 95.81% of US stocks.
Apollo Endosurgery Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -51.28%, greater than the shareholder yield of merely 8.31% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Apollo Endosurgery Inc, a group of peers worth examining would be ALIM, QTT, ADMS, CMPR, and NLST.
Apollo Endosurgery, Inc. focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system, a non-surgical alternative for the treatment of overweight and obese adults; and OverStitch, an endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through an Olympus dual-channel flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company is based in Austin, Texas.
AUSTIN, TX / ACCESSWIRE / April 13, 2020 / Apollo Endosurgery, Inc. ("Apollo") (APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that the US Food and Drug Administration (FDA) has completed the review of the final Post-Approval Study (PAS) Report for the Orbera Intragastric Balloon System and accepted that all post-approval study requirements have been fulfilled. The ORBERA Post Approval Study was a requirement following the US FDA's approval of ORBERA in August of 2015.